Technological Offers

Method to predict response to immunotherapy in patients with cutaneous melanoma

Description


Cancer is one of the most studied diseases in recent years, due to its high incidence and mortality. There are different types of cancer depending on the tissue and/or organ affected, one of them is melanoma, which is an aggressive malignant tumor of the epidermal melanocytes.

El Cutaneous melanoma cada vez presenta unas tasas de incidencia mayores en el mundo occidental. Si el melanoma cutáneo se vuelve metastásico, las opciones de tratamiento y las posibilidades de supervivencia disminuyen drásticamente.

Today, there are different treatments depending on the type of cancer. Among these, immunotherapy treatments based on immune checkpoint inhibitors (PD-1 and CLTA4) have been a breakthrough in the treatment of metastatic cutaneous melanoma.

The problem is that a percentage of patients are insensitive or develop resistance, so it is necessary to have a pattern of predictive biomarkers to decide whether or not to use anti-PD1 and CLT4.

To this end, a research group has identified a ceRNA molecular biomarker profile, which allows patients to be classified according to their response profile, based on gene expression variations. This profile makes it possible to classify patients into responders (partial, complete or stable) or non-responders (severe or not severe), allowing for more individualized treatment and follow-up for each patient.

Advantages


  • It It allows to determine in advance whether anti-PD1/anti-CLT4 treatment is appropriate for the patient with metastatic cutaneous melanoma. para el paciente que padece melanoma cutáneo metastásico.
  • It reduces the economic costs and adverse effects associated with the use of unresponsive treatments for certain patients.
  • It improves personalized treatment options and therefore the healthcare and quality of life of patients.

Diagnosis


IBIMA Plataforma BIONAND inventors


MARÍA ISABEL BARRAGÁN MALLOFRET
Research group of IBIMA involved: CIMO-02

FRANCISCO JAVIER OLIVER MARTOS
Research group of IBIMA involved: CIMO-02

JUAN LUIS ONIEVA ZAFRA
Research group of IBIMA involved: CIMO-02

ANTONIO RUEDA DOMÍNGUEZ
Research group of IBIMA involved: CIMO-02

ELISABETH PÉREZ RUIZ
Research group of IBIMA involved: CIMO-02

MIGUEL ÁNGEL BERCIANO GUERRERO
Research group of IBIMA involved: CIMO-02

EMILIO ALBA CONEJO
Research group of IBIMA involved: CIMO-01

Contact


Innovation and Technology Transfer Office of IBIMA Plataforma BIONAND

[email protected]